| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
Department of Respiratory Medicine,
Molecular Preventive Medicine, and Core Research for Evolutional Science and Technology, School of Medicine, University of Tokyo, Tokyo, Japan;
Second Department of Physiology, Showa University School of Medicine, Tokyo, Japan; and
Department of Bacteriology, Kinki University School of Medicine, Osaka, Japan
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Chemokines, a family of low m.w. proteins that induce specific types of leukocyte chemotaxis, play essential roles in regulating the extravasation and tissue accumulation of a certain cell type during immune and inflammatory responses (14, 15, 16). Recent investigations have revealed the existence of a number of novel lymphocyte-directed chemokines (17, 18, 19). Among these CC chemokines, thymus- and activation-regulated chemokine (TARC) is the first CC chemokine to be shown to selectively chemoattract T lymphocyte (17). TARC was subsequently identified to be a specific ligand for CC chemokine receptor 4 (CCR4) (18) and to induce chemotaxis of T cells, especially of the Th2 type CD4+ human T lymphocytes (20, 21, 22). However, the in vivo pathophysiological roles of TARC remain largely unknown.
In the present studies we addressed the question of whether TARC has any effect on the development of airway eosinophilia as well as AHR in the allergic airway inflammation mimicking those seen in bronchial asthma.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Specific pathogen-free male C57BL/6 mice (6–8 wk old) were obtained from CLEA Japan (Tokyo, Japan) and bred in a pathogen-free mouse facility of the Department of Molecular Preventive Medicine. All animal experiments complied with the standards set out in the guidelines of University of Tokyo.
Reagents
OVA was purchased from Sigma (St. Louis, MO). Hamster anti-mouse TARC mAb 5H5 was prepared as described previously (23, 24). The specificity of this Ab was evaluated by 1) binding assay using ELISA, 2) calcium mobilization assay, and 3) chemotaxis assay as described below.
Direct ELISA
The specificity of monoclonal anti-mouse TARC 5H5 was
examined by a direct ELISAs. Recombinant mouse chemokines used for the
assay were TARC, liver and activation-regulated chemokine/macrophage
inflammatory protein-3
(MIP-3), macrophage-derived chemokine
(MDC), secondary lymphoid chemokine/6Ckine, EBI1-ligand
chemokine/MIP-3
, stromal-derived factor-1, RANTES, lymphotactin,
MIP-1, monocyte chemotactic protein-1 (JE), and IL-11 receptor
locus chemokine/cutaneous T cell-attracting chemokine. They were
purchased from PeproTech (Rocky Hill, NJ). In brief, ELISA plates
(Costar, Cambridge, MA) were coated with recombinant mouse chemokines
at a concentration of 2 µg/ml and incubated at 37°C overnight.
After washing with PBS containing 0.05% Tween 20 (PBS-T), plates were
blocked with PBS containing 1% BSA, 5% sucrose, and 0.05%
NaN3. After washing with PBS-T, 5H5 was added at
a concentration of 2 µg/ml and incubated at 37°C for 1 h.
After washing with PBS-T, plates were incubated at 37°C for 30 min
with biotinylated goat anti-hamster IgG (Vector, Burlingame, CA) at
a concentration of 5 µg/ml. After washing with PBS-T, plates were
incubated at 37°C for 30 min with HRP-streptavidin (Vector). After
washing with PBS-T, bound HRP was developed by tetramethylbenzidine
substrate, and OD at 450 nm was measured using a microplate reader.
Calcium mobilization assay
This was conducted using mouse L1.2 pre-B cells stably transfected with mouse CCR4 cDNA as previously described (18). In brief, cells were suspended at 1 x 106 cells/ml in HBSS containing 1 mg/ml of BSA and 10 mM HEPES, pH 7.4 (HBSS-BSA), and incubated with 3 mM fura-2/AM fluorescence dye (Molecular Probes, Eugene, OR) at room temperature for 1 h in the dark. After washing twice, cells were resuspended at 5 x 106 cells/ml. Cells in 0.1 ml were placed into a fluorescence spectrophotometer (F2000; Hitachi, Tokyo, Japan). Mouse TARC (mTARC; 10 nM) or mouse MDC (mMDC) was added to cells in 0.1 ml in the absence or the presence of 5H5 at the indicated concentrations, and emission fluorescence at 510 nm was measured upon excitation at 340 and 380 nm with a time resolution of 5 points to obtain the fluorescence intensity ratio (R340/380).
Chemotaxis assay
L1.2 pre-B cells stably transfected with mouse CCR4 were washed twice with phenol red-free RPMI 1640 medium containing 1 mg/ml BSA, and 0.1 ml of cell suspension containing 2.5 x 105 cells was applied to each of the upper wells of a Transwell plate (3-mm pore size; Costar). Mouse TARC or mouse MDC at 10 nM was preincubated with or without the indicated concentrations of 5H5 for 30 min and added to the lower wells in a volume of 0.6 ml. After 4 h at 37°C migrated cells were determined by measuring dsDNA with PicoGreen dsDNA quantitation reagent (Molecular Probes). Values were expressed as the percentage of input cells that migrated to the lower wells. All assays were performed in triplicate.
Induction of murine asthma model
Pulmonary eosinophilia in response to OVA was generated in mice as described previously (25, 26). In this experience we modified this model. In brief, the murine model of lung eosinophilia used here consists of an initial phase of sensitization and a second phase of induction of the allergic response. Mice were first sensitized with i.p. injection of OVA (0.1 mg/mouse) in 0.2 M PBS/alum (Sigma) on days 1 and 8. The mice were challenged by inhalation of aerosolized 1% OVA for 20 min on days 15–21 to induce the response. At different times after the last allergen challenge, animals were killed under anesthesia with barbiturate. PBS (i.p. and aerosolized) was administered to mice on a similar schedule as in negative controls.
Effect of anti-TARC Ab
In the series of blocking experiments, mice were injected with neutralizing mAb against mTARC 5H5 (50 µg/mouse i.p.) 30 min before OVA administration on days 8–21, and then analyzed 6 h after allergen challenge on day 21. OVA-treated control mice were injected with the same amount of control Ab (hamster Ig fraction; Dako, Santa Barbara, CA) at the same time points as during the treatments. The dose and time schedules of Ab treatment were basically decided according to previous reports with similar experimental strategy (27).
Bronchoalveolar lavage (BAL)
BAL was performed as previously described (11). Briefly, at various time points after the last aerosol exposure, the lungs were lavaged via a tracheal cannula with 0.7 ml of PBS three times. The recovered BAL fluid was immediately centrifuged (1000 rpm, 2 min, 4°C), and cells in BAL fluid were washed twice and resuspended in 1 ml of PBS. The number of cells was determined by hemocytometer. Samples were applied to glass slides by cytocentrifugation (5 x 105 cells/slide), air-dried for 10 min, and then subjected to Wright-Giemsa stain (Fisher Diagnostics, Pittsburgh, PA). The percentages of eosinophils, lymphocytes, neutrophils, and macrophages were determined by counting at least 500 cells/slide using standard morphologic criteria.
Histology
Lung specimens were fixed in 10% neutrally buffered formalin and paraffin embedded. Deparaffinized sections (3 µm thick) were stained with hematoxylin and eosin and analyzed under a light microscope.
Immunohistochemistry
Lung specimens were embedded in Tissue-Tek OCT compound (Miles, Elkhart, IN), frozen in liquid nitrogen, and cut by a cryostat into 7-µm-thick sections. After inhibition of endogenous peroxidase activity (28), the sections were incubated with hamster anti-mouse TARC mAb (5H5) or rat anti-mouse CD4 mAb (RM4-5; PharMingen, San Diego, CA). Hamster anti-mouse TARC mAb (5H5)-treated sections were incubated sequentially with HRP-conjugated anti-hamster IgG (Southern Biotechnology Associates, Birmingham, AL). Rat anti-mouse CD4 mAb (RM4-5; PharMingen)-treated sections were incubated with alkaline phosphatase-labeled anti-rat IgG and anti-hamster IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), respectively. After visualization with 3,3'-diaminobenzidine (Wako Chemicals, Dallas, TX) or alkaline phosphatase substrate kit I (Vector), slides were counterstained with Mayer’s hematoxylin. Control hamster (Rockland, Gibertsville, PA) and rat (Sigma) IgG did not stain the same samples in any experiments (10).
Fluorescent immunohistochemistry
To better identify the cell types that were stained for TARC protein, we performed studies with fluorescent microfluorographs. After inhibition of endogenous peroxidase activity, the sections were incubated with hamster anti-mouse CD11c mAb (N418, Serotec, Oxford, U.K.). Hamster anti-mouse CD11c mAb (N418, Serotec)-treated sections were incubated with alkaline phosphatase-labeled anti-hamster IgG (Jackson ImmunoResearch Laboratories). After visualization with alkaline phosphatase substrate kit I (Vector), the sections were washed with water and PBS. After inhibition of endogenous peroxidase activity, the sections were incubated with hamster anti-mouse TARC mAb (5H5). Hamster anti-mouse TARC mAb (5H5)-treated sections were incubated sequentially with FITC-conjugated anti-hamster IgG (Southern Biotechnology Associates). To enhance the fluorescent staining, the sections were incubated with FITC-conjugated anti-FITC IgG (Southern Biotechnology Associates). CD11c mAb (red) and TARC mAb (green) fluorescence could be examined simultaneously under epifluorescence microscope at a wavelength exciting FITC (490 nm). Control hamster IgG (Rockland) did not stain the same samples in any experiment. In these studies TARC expression was stained in green, whereas CD11c-positive cells were stained in red. In addition, negative cells were visualized by a transillumination with a green filter (29).
Chemokine and cytokine gene expression analysis in the lung
Total RNA was isolated from lung specimens using RNAzol (Biotecx, Houston, TX), according to the manufacturer’s instructions, reverse transcribed into cDNA, and amplified. The levels of cytokine and chemokine expressions were determined with the novel method of real-time quantitative PCR using the ABI 7700 sequence detector system (PE Applied Biosystems, Foster City, CA) (18). The sense primer for TARC was 5'-CAGGAAGTTGGTGAGCTGGTATA-3', and the antisense primer was 5'-TTGTGTTCGCCTGTAGTGCATA-3'. The sense primer for GAPDH was 5'-AGTATGACTCCACTCACGGCAA-3', and the antisense primer was 5'-TCTCGCTCCTGGAAGATGGT-3'. The sense primer for eotaxin was 5'-AGAGCTCCACAGCGCTTCTATT-3', and the antisense primer was 5'-GGTGCATCTGTTGTTGGTGATT-3'. The sense primer for RANTES was 5'-CATATGGCTCGGACACCACT-3', and the antisense primer was 5'-ACACACTTGGCGGTTCCTTC-3'. The sense primer for MDC was 5'-TCTGATGCAGGTCCCTATGGT-3', and the antisense primer was 5'-TTATGGAGTAGCTTCTTCACCCAG-3'. The reaction master mix containing a cDNA sample was prepared according to the manufacturer’s protocols to yield final concentrations of 1x PCR buffer A; 200 mM dATP, dCTP, and dGTP; 400 mM dUTP; 4 mM MgCl2; 1.25 U AmpliTaq DNA polymerase; 0.5 U Amp-Erase uracil-N-glycosylase; and 200 mM of each primer. The reactions also contained the following target hybridization probes (100 mM each). TARC probe was 5'-ATGCCATCGTGTTTCTGACTGTCCAGG-3'. GAPDH probe was 5'-AACGGCACAGTCAAGGCCGAGAAT-3'. Eotaxin probe was 5'-TGCTCACGGTCACTTCCTTCACCT-3'. RANTES probe was 5'-CAAGTGCTCCAATCTTGCAGTCGTG-3'. MDC probe was 5'-CCAATGTGGAAGACAGTATCTGCTGCCA-3'. The probe was labeled with a reporter fluorescent dye, FAM (6-carboxyfluorescein), at the 5' end. The thermal cycling conditions included 50°C for 2 min and 95°C for 10 min, followed by 50 cycles of amplification at 95°C for 15 s and 55°C for 1.5 min for denaturing and annealing-extension, respectively. The PCR products were also examined by 2% agarose gel electrophoresis. After ethidium bromide staining, bands were visible only at the expected m.w. for each target mRNA product.
Measurement of cytokine production
The release of cytokines in anti-TARC Ab-treated sensitized
mice or control Ab-treated sensitized littermates was determined by
ELISA. BAL fluids were collected 48 h after Ag challenge on day
21. BAL fluids concentrated by freeze-drying were assayed using
commercially available ELISA kits for IL-4, IL-13, and IFN-
(Endogen, Boston, MA). Absorbance values were converted to the
concentration of each cytokine in the BAL fluid (picograms per
milliliter) by interpolation to the respective standard curve. The
detection limits of the assay for IFN-, IL-4, and IL-13 were 8, 9,
and 9 pg/ml, respectively.
Measurement of specific airway responsiveness (sRaw)
We measured the sRaw (centimeters of H2O per liter per second) in unanesthetized mice with the double-chamber plethysmograph (27) on day 23. The noninvasive technique is based on measurement of the time delay between thoracic and mouth volume changes, and we calculated the airway resistance (30, 31). Airway responsiveness to i.v. methacholine challenge was defined by the sRaw. In brief, mice were positioned in the double chamber. Preliminary experiments demonstrated a significant dose-response relationship between the methacholine dose and the sRaw, where 50 mg/kg of methacholine seemed an optimal dose (data not shown). After establishment of a stable state, methacholine was injected i.v. (50 mg/kg), and sRaw was measured for 5 min.
Measurement of the number of CD4-positive cells
CD4-positive cells were quantified in the area 100 µm beneath the epithelial basement membrane in several nonoverlapping high power fields until all the available area was covered. The final result, expressed as the number of positive cells per square millimeter, was calculated as the average of all cellular counts.
Statistical analysis
Results are expressed as the mean ± SE. Statistical significance analyses were performed unless otherwise indicated by two-way ANOVA, and multiple comparisons were made by Fisher’s test. p < 0.05 was accepted as statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The specificity of anti-mouse TARC mAb 5H5 was first examined
by a direct ELISA. 5H5 bound only to recombinant mouse TARC protein but
not to other tested mouse CC chemokines, including MDC, liver and
activation-regulated chemokine/MIP-3, secondary lymphoid
chemokine/6Ckine, EBI1-ligand chemokine/MIP-3, stromal-derived
factor-1, RANTES, lymphotactin, MIP-1, MCP-1 (JE), and IL-11
receptor locus chemokine/cutaneous T cell-attracting chemokine.
Furthermore, we checked the cross-reactivity of 5H5 with mMDC by
measuring the calcium mobilization and chemotaxis in mouse L1.2 pre-B
cells that were stably transfected with mouse CCR4 cDNA. 5H5 completely
inhibited mouse TARC-induced calcium mobilization (Fig. 1
A) and chemotaxis (Fig.
1B). In contrast, such inhibition was not seen in mouse
MDC-induced calcium mobilization or chemotaxis. Thus, 5H5 was concluded
to be a highly specific neutralizing mAb to mouse TARC and was used for
in vivo administration and the immunohistochemical studies described
below.
|
To evaluate the changes in TARC mRNA expression during the
development of a murine model of asthma, total lung RNA was extracted
3, 6, 24, and 48 h after the last Ag inhalation (on day 21), and
the levels of TARC mRNA were examined by a real-time quantitative PCR.
Lung TARC mRNA expression was detectable in the untreated lung, which
was significantly increased at 3–6 h after the last OVA challenge, and
the levels were subsequently enhanced up to 24 h (Fig. 2).
|
To confirm the production of TARC protein and to identify the
producing cells in the lung, immunohistochemical staining was
performed. Bronchial epithelial cells specifically expressed TARC in
the lung of untreated animals (Fig. 3B). We studied TARC
expression by immunohistochemical analysis 3, 6, 24, and 48 h
after the last Ag inhalation. The results showed that the expression
peaked at 6 h (data not shown). In the OVA-treated group, there
was strong staining for TARC, mainly in bronchial epithelium,
peribronchial lesions, and infiltrating cells (Fig. 3C). To
better identify the cell types that were stained for TARC protein
expression, we performed studies using fluorescent microfluorographs.
We chose CD11c, since TARC is known to be preferentially produced by
DC, and CD11c (leukocyte integrin CR4 subunit) has been used as a
marker for most dendritic cells (32). TARC expression was
stained in green, and CD11c-positive cells were stained in red.
Peripheral bronchial epithelial cells and endothelial cells (Fig. 3E) were stained in green, namely those expressing TARC
protein. In contrast, CD11c-positive cells adjacent to this kind of
structural cell were rarely stained in yellow (double positive).
|
To evaluate the specific contribution of TARC to the development
of lung inflammation in this OVA model, blocking experiments of this
chemokine were performed using specific neutralizing Ab. First, we
examined the cell profiles of BAL fluids in groups of anti-TARC
Ab-treated and control Ab-treated mice. There were marked increases in
total cell number, mostly eosinophils, but also macrophages and
lymphocytes, in BAL fluids obtained from OVA-treated mice as described
previously (11) (Fig. 4).
Control Ab did not affect any of the changes induced by OVA treatment
in this model of asthma (Fig. 4). Treatment with anti-TARC Ab
strikingly decreased the total cell number and the number of
eosinophils as well as lymphocytes recovered in the lavage fluid
compared with those in the group treated with control Ab (Fig. 4). In
contrast, the number of macrophages was not changed by treatment with
anti-TARC Abs. These results established that TARC played a pivotal
role in the induction of lymphocyte and eosinophil infiltration in the
airways.
|
In accordance with the changes found in BAL fluid preparations,
neutralization of TARC reduced the number of infiltrating cells into
the lung in response to OVA, most of which appeared to be mononuclear
lymphocytes and eosinophils by hematoxylin-eosin and Wright-Giemsa
stainings (Fig. 5, A–D).
|
Eosinophilic inflammation is clearly a hallmark of allergic
asthma, and considerable evidence suggests an association between
pulmonary eosinophil infiltration and AHR in human asthma
(33). To determine the role of TARC in the development of
allergen-induced AHR, measurements of airway reactivity to i.v.
methacholine were performed on day 23. Animals sensitized and
challenged by OVA with the treatment of control Ab showed significantly
higher sRaw in response to methacholine compared with saline control
animals given control Ab (Fig. 6). The
baseline sRaw tended to be higher than that in unsensitized animals,
but the difference was not significant. OVA-sensitized and challenged
mice treated with anti-TARC Ab showed significantly lower sRaw in
response to methacholine compared with those treated with control Ab
(Fig. 6). With the anti-TARC Ab treatment, the increase in sRaw was
inhibited by 64% (p < 0.005), and the sRaw
was not significantly different from that in the control group (saline
injection and saline inhalation) at each time point after methacholine
injection. The difference in baseline airway resistance is due to Ag
exposure without methacholine. These results indicate that the
development of Ag-induced AHR was significantly decreased with
anti-TARC Ab.
|
To elucidate whether anti-TARC mAb inhibited T lymphocyte
infiltration in the lung, we also evaluated the number of
CD4+ T cells in the airways by anti-TARC Ab
treatment. Anti-TARC mAb treatment markedly decreased the degree of
infiltration of CD4+ T cells (number of
CD4-positive cells per square millimeter, 58.5 ± 6.19 (±SEM) and
26.5 ± 3.00 (±SEM) in control Ab group and, anti-TARC Ab
group, respectively; p < 0.001, by Student’s
t test; Fig. 5
, E and F).
Anti-TARC Ab selectively suppressed the local concentrations of Th2-type cytokines in the lung
Th2 cytokines such as IL-4 and IL-13 are required for pulmonary
eosinophilia and induction of AHR (9, 33). To determine
whether the blockage of TARC shows any effect on the local production
of these cytokines in this model of asthma, we measured the levels of
IL-4 and IL-13 as well as that of a Th1-type cytokine IFN-. BAL
fluids were obtained 48 h after last OVA inhalation, and IL-4 and
IL-13 levels were significantly increased in the OVA treatment group
(Fig. 7). Blockage of TARC significantly
decreased OVA-induced production of these two cytokines. The levels of
IFN- in BAL fluids were not statistically different between the
groups given control Ab treatment and those given TARC Ab treatment at
48 h after the last OVA inhalation (Fig. 7).
|
To evaluate the changes in chemokine expression during the
development of a murine model of asthma, the levels of eotaxin, RANTES,
and MDC mRNA were examined by a real-time quantitative PCR. Lung
eotaxin mRNA expression was detectable in the untreated lung, which was
significantly increased at 6–24 h after the last OVA challenge, and
the levels were suppressed by anti-TARC Ab (Fig. 8A). Lung RANTES mRNA
expression was increased, but not significantly, after OVA challenge,
and the levels tended to be reduced, but were not significantly
changed, by anti-TARC Ab (Fig. 8B). MDC mRNA
expression was significantly increased after OVA challenge, but
anti-TARC Ab treatment did not significantly affect MDC mRNA
expression (Fig. 8C).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A number of clinical studies showed that there was an intense infiltration of inflammatory cells, including T cells, especially CD4+ cells, as well as eosinophils. There was a significant correlation between the number of CD4+ cells in BAL fluids and the degree of AHR in asthmatic patients (34). Increasing evidence suggests that T lymphocytes, in particular CD4+ T cells of the Th2 type, play an essential role in the development of the eosinophilic inflammatory response commonly found in asthma (35, 36). Elevated IL-4, IL-5, and IL-13 levels in bronchial biopsies (36, 37), BAL cells, and blood (37) of allergic asthmatic patients have been reported, and therefore, it is suggested that these Th2-type cytokines play a key role in the eosinophil accumulation and resultant AHR found in asthmatics.
To further elucidate the roles of the Th2 cells and their cytokines, experimental models of asthma have been used. Mice sensitized with OVA showed maximal lung monocyte/macrophage accumulation at early stages of inflammatory response, followed by an increase in eosinophil and T lymphocyte numbers at later stages of the response (11). IL-4, IL-5, and IL-13 (4, 5, 6, 7) have been strongly implicated in generating and perpetuating the late phase asthmatic response, including recruitment of activated eosinophils into airways, AHR, and airflow limitation (8, 9, 10). Recent reports using T1/ST2-deficient mice (38) strongly suggested that Th2 cells play an essential role in the development of asthmatic airway inflammation. However, it remains unclear how the recruitment of T cells, especially CD4+ cells, into the lung is elicited during allergic inflammation. It is likely that certain chemokines play roles in trafficking effector T lymphocytes into inflamed areas of the lung.
TARC is the first CC chemokine to be shown to selectively chemoattract
T lymphocytes (17). TARC was subsequently identified to be
a specific ligand for CCR4 (18) and to be a selective
chemoattractant for T cells, especially of the Th2 type
CD4+ human T lymphocytes (20, 21, 22).
TARC has been reported to be expressed in dendritic cells and possibly
in macrophages. In the present experiment we performed fluorescent
microfluorographic studies. TARC was stained in green, and
CD11c-positive cells were stained in red as a marker for dendritic
cells (32). The results suggested that bronchial
epithelial cells and endothelial cells were potential sources of this
chemokine (Fig. 3E).
Since the number of inflammatory cells in the BAL might be different from that in the tissue itself, we also studied the degree of CD4-positive cell infiltrates in the tissues. Our present findings of blocking experiments with anti-TARC Ab clearly indicated that inhibition of TARC decreased BAL lymphocytes and airway infiltration of CD4-positive T cells, possibly Th2 cells, which produce Th2 cytokines such as IL-4 and IL-13. Decreased local production of these cytokines seemed to attenuate eosinophil accumulation and the following AHR (39, 40) in a number of ways. Since Th2 cells themselves are capable of producing chemokines, a decrease in Th2 cells-derived chemokines such as RANTES might be involved. Besides, recent studies emphasized the importance of airway epithelium-derived chemokines, including eotaxin, in the pathogenesis of asthma (41). Airway epithelial cells produce these chemokines in response to Th2 type cytokines, including IL-4 and IL-13 from T cells (42, 43). Finally, locally recruited eosinophils also produce chemoattractants for themselves, such as RANTES, eotaxin, and lipids such as leukotriene C4 and platelet-activating factor (41).
Treatment with anti-TARC Ab dramatically decreased the number of eosinophils in BAL samples and histology. Studies of mRNA levels of eotaxin in the lung clearly showed a decrease after anti-TARC treatment, whereas the levels of RANTES did not significantly change, suggesting that decreased eotaxin expression might be predominantly involved in this setting.
There is accumulating evidence that shows a critical role for a variety
of chemokines in the sequential local migration of inflammatory cells.
Gonzalo and colleagues (44) indicated that the coordinated
action of CC chemokines in the lung orchestrates allergic inflammation
and airway hyper-responsiveness in a murine model of asthma. RANTES
expression was up-regulated during the early phase of airway
inflammation, suggesting a role in the development of asthma. However,
another report (45) failed to show the significance of
this CC chemokine in asthma. In our model of asthma, quantitative
evaluation of RANTES mRNA expression did not show any significant
change (Fig. 8B); therefore, its importance remains
unknown.
Recent investigations have revealed that CCR3 and CCR4 are expressed on
Th2 cells, whereas CCR5 is preferentially expressed on Th1 cells
(15, 21, 22, 46, 47). The ligands for CCR4 include a CC
chemokine MDC in addition to TARC. MDC not only shares CCR4 with TARC
as its specific receptor, but also shows several common features with
TARC: it has 32% homology with TARC in amino acid sequence and is a
potent chemokine for T cells (48). MDC has been reported
to be expressed by dendritic cells, which also produce TARC. Gonzalo et
al. (49) described the role of MDC in a murine asthma
model similar to ours. In their hands, blocking of MDC by the
polyclonal Ab resulted in prevention of AHR associated with significant
reduction of infiltratory eosinophils in the lung interstitium, but not
in BAL (49). Since the mAb against TARC used in our
experiments was highly specific for TARC and did not cross-react with
MDC (Fig. 1, A and B), our data strongly suggest
that TARC is also an essential chemokine for T cells in the development
of allergic inflammation in addition to MDC, although further study is
necessary to better elucidate the mutual roles of TARC and MDC in T
cell migration.
It would be important to study CCR4 expression on CD4+ infiltrating T lymphocytes in the airways. We attempted to study CCR4 expression on BAL cells by FACS, but the commercially available Ab (Santa Cruz Biotechnology, Santa Cruz, CA) detects the C-terminals of intracellular domains of CCR4, and therefore, it was unsuccessful. As for the results obtained by cryostat sections, there was an intense staining for airway epithelial cells and endothelial cells, and accurate evaluation of CCR4-positive T cells were not possible (data not shown).
During the preparation of this manuscript, an important paper appeared related to this study. Chvatchko et al. reported that CCR4 deletion had no effect on a Th2-dependent model of allergic airway inflammation in mice (50). However, we must keep in mind that the findings obtained from their knockout mice cannot always be applied to the actual pathophysiology of the disease, because they are mature animals that have lacked the targeted gene since birth. In our studies we directly assessed the importance of TARC in the development of a murine model of asthma using anti-TARC-specific neutralizing mAb and found that 1) the expression of TARC was constitutively seen in the lung and was up-regulated in murine models of allergic asthma; 2) the specific Ab against TARC attenuated OVA-induced airway eosinophilia, the degree of AHR, and the infiltration of CD4+ cells in the airways; and 3) this Ab also decreased Th2 cytokine levels and eosinophilic cytokine expression in the lung. Recently, it was reported that TARC also binds to CCR8 to induce chemotaxis (51). Therefore, it is possible that TARC might be involved in allergic airway inflammation via binding to CCR8 as well as CCR4.
In conclusion, our results demonstrate that a CC chemokine, TARC, is essentially involved in the development of AHR and eosinophilia through the recruitment of Th2-type CD4-positive T lymphocytes in a murine model of bronchial asthma. Therefore, TARC could be a novel target for intervention therapy of asthma.
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kouji Matsushima, Department of Molecular Preventive Medicine, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
3 Abbreviations used in this paper: AHR, airway hyperresponsiveness; TARC, thymus- and activation-regulated chemokine; mTARC, mouse TARC; CCR, CC chemokine receptor; MIP-1, macrophage inflammatory protein 1; MDC, macrophage-derived chemokine; BAL, bronchoalveolar lavage; sRaw, specific airway resistance; PBS-T, PBS containing 0.05% Tween 20.
Received for publication June 12, 2000. Accepted for publication November 10, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. J. Exp. Med. 174:547. induce the migration and activation of normal human eosinophil granulocytes. J. Exp. Med. 176:1489. as novel functional ligands for the CCR8 receptor. Eur. J. Immunol. 28:582.[Medline]This article has been cited by other articles:
|
|
 |
|
  J. Kearley, K. F. Buckland, S. A. Mathie, and C. M. Lloyd Resolution of Allergic Inflammation and Airway Hyperreactivity Is Dependent upon Disruption of the T1/ST2-IL-33 Pathway Am. J. Respir. Crit. Care Med., May 1, 2009; 179(9): 772 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stevens, S.-H. Cho, W. P. Linak, and M. I. Gilmour Differential Potentiation of Allergic Lung Disease in Mice Exposed to Chemically Distinct Diesel Samples Toxicol. Sci., February 1, 2009; 107(2): 522 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Medoff, E. Seung, S. Hong, S. Y. Thomas, B. P. Sandall, J. S. Duffield, D. A. Kuperman, D. J. Erle, and A. D. Luster CD11b+ Myeloid Cells Are the Key Mediators of Th2 Cell Homing into the Airway in Allergic Inflammation J. Immunol., January 1, 2009; 182(1): 623 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Olson, S. M. Hartwig, and S. M. Varga The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia J. Immunol., December 1, 2008; 181(11): 7958 - 7968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Saito, M. Torii, N. Ma, T. Tsuchiya, L. Wang, T. Hori, D. Nagakubo, N. Nitta, S. Kanegasaki, K. Hieshima, et al. Differential Regulatory Function of Resting and Preactivated Allergen-Specific CD4+CD25+ Regulatory T Cells in Th2-Type Airway Inflammation J. Immunol., November 15, 2008; 181(10): 6889 - 6897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Traeger, W. Kessler, V. Assfalg, K. Cziupka, P. Koerner, C. Dassow, K. Breitbach, M. Mikulcak, I. Steinmetz, K. Pfeffer, et al. Detrimental Role of CC Chemokine Receptor 4 in Murine Polymicrobial Sepsis Infect. Immun., November 1, 2008; 76(11): 5285 - 5293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ying, B. O'Connor, J. Ratoff, Q. Meng, C. Fang, D. Cousins, G. Zhang, S. Gu, Z. Gao, B. Shamji, et al. Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease J. Immunol., August 15, 2008; 181(4): 2790 - 2798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. Pokharel, S. C. Lim, S. C. Kim, T.-H. Heo, H. K. Choi, and K. W. Kang Sopungyangjae-Tang Inhibits Development of Dermatitis in Nc/Nga Mice Evid. Based Complement. Altern. Med., June 1, 2008; 5(2): 173 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nonaka, N. Ogihara, A. Fukumoto, A. Sakanushi, R. Pawankar, and T. Yagi Combined Stimulation of Nasal Polyp Fibroblasts With Poly IC, Interleukin 4, and Tumor Necrosis Factor {alpha} Potently Induces Production of Thymus- and Activation-Regulated Chemokine Arch Otolaryngol Head Neck Surg, June 1, 2008; 134(6): 630 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mellado, A. M. de Ana, L. Gomez, C. Martinez-A, and J. M. Rodriguez-Frade Chemokine Receptor 2 Blockade Prevents Asthma in a Cynomolgus Monkey Model J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 769 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ashino, D. Wakita, Y. Zhang, K. Chamoto, H. Kitamura, and T. Nishimura CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung Int. Immunol., February 1, 2008; 20(2): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Lee, W. Sukhumavasi, and E. Y. Denkers Phosphoinositide-3-Kinase-Dependent, MyD88-Independent Induction of CC-Type Chemokines Characterizes the Macrophage Response to Toxoplasma gondii Strains with High Virulence Infect. Immun., December 1, 2007; 75(12): 5788 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Knight, A. B. Blazquez, S. Zhang, L. Mayer, H. A. Sampson, and M. C. Berin CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1234 - G1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Jaffar, M. E. Ferrini, M. C. Buford, G. A. FitzGerald, and K. Roberts Prostaglandin I2-IP Signaling Blocks Allergic Pulmonary Inflammation by Preventing Recruitment of CD4+ Th2 Cells into the Airways in a Mouse Model of Asthma J. Immunol., November 1, 2007; 179(9): 6193 - 6203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Meyer, M.-A. Wurbel, T. L. Staton, M. Pichavant, M. J. Kan, P. B. Savage, R. H. DeKruyff, E. C. Butcher, J. J. Campbell, and D. T. Umetsu iNKT Cells Require CCR4 to Localize to the Airways and to Induce Airway Hyperreactivity J. Immunol., October 1, 2007; 179(7): 4661 - 4671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mori, K. Ogawa, K. Someya, Y. Kunori, D. Nagakubo, O. Yoshie, F. Kitamura, T. Hiroi, and O. Kaminuma Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists Int. Immunol., August 1, 2007; 19(8): 913 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Simeone-Penney, M. Severgnini, P. Tu, R. J. Homer, T. J. Mariani, L. Cohn, and A. R. Simon Airway Epithelial STAT3 Is Required for Allergic Inflammation in a Murine Model of Asthma J. Immunol., May 15, 2007; 178(10): 6191 - 6199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Beaty, C. E. Rose Jr., and S.-s. J. Sung Diverse and Potent Chemokine Production by Lung CD11bhigh Dendritic Cells in Homeostasis and in Allergic Lung Inflammation J. Immunol., February 1, 2007; 178(3): 1882 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Ness, J. L. Ewing, C. M. Hogaboam, and S. L. Kunkel CCR4 Is a Key Modulator of Innate Immune Responses J. Immunol., December 1, 2006; 177(11): 7531 - 7539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schnyder-Candrian, D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. Fossiez, B. Ryffel, and B. Schnyder Interleukin-17 is a negative regulator of established allergic asthma J. Exp. Med., November 27, 2006; 203(12): 2715 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hartl, P. Latzin, G. Zissel, M. Krane, S. Krauss-Etschmann, and M. Griese Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Cronshaw, A. Kouroumalis, R. Parry, A. Webb, Z. Brown, and S. G. Ward Evidence that phospholipase C-dependent, calcium-independent mechanisms are required for directional migration of T lymphocytes in response to the CCR4 ligands CCL17 and CCL22 J. Leukoc. Biol., June 1, 2006; 79(6): 1369 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Maezawa, H. Nakajima, K. Suzuki, T. Tamachi, K. Ikeda, J.-i. Inoue, Y. Saito, and I. Iwamoto Involvement of TNF Receptor-Associated Factor 6 in IL-25 Receptor Signaling J. Immunol., January 15, 2006; 176(2): 1013 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yang, B. E. Castle, A. Hanidu, L. Stevens, Y. Yu, X. Li, C. Stearns, V. Papov, D. Rajotte, and J. Li Sphingosine Kinase 1 Is a Negative Regulator of CD4+ Th1 Cells J. Immunol., November 15, 2005; 175(10): 6580 - 6588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Carpenter and C. M. Hogaboam Immunosuppressive Effects of CCL17 on Pulmonary Antifungal Responses during Pulmonary Invasive Aspergillosis Infect. Immun., November 1, 2005; 73(11): 7198 - 7207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Kawashima, N Oshitani, Y Jinno, K Watanabe, S Nakamura, K Higuchi, and T Arakawa Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn's disease J. Clin. Pathol., October 1, 2005; 58(10): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Al-Shami, R. Spolski, J. Kelly, A. Keane-Myers, and W. J. Leonard A role for TSLP in the development of inflammation in an asthma model J. Exp. Med., September 19, 2005; 202(6): 829 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Moerloose, R. A. Pauwels, and G. F. Joos Short-Term Cigarette Smoke Exposure Enhances Allergic Airway Inflammation in Mice Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 168 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Heijink, E. Vellenga, J. Oostendorp, J. G. R. de Monchy, D. S. Postma, and H. F. Kauffman Exposure to TARC alters {beta}2-adrenergic receptor signaling in human peripheral blood T lymphocytes Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L53 - L59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ying, B. O'Connor, J. Ratoff, Q. Meng, K. Mallett, D. Cousins, D. Robinson, G. Zhang, J. Zhao, T. H. Lee, et al. Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of Th2-Attracting Chemokines and Disease Severity J. Immunol., June 15, 2005; 174(12): 8183 - 8190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Akadegawa, S. Ishikawa, T. Sato, J. Suzuki, H. Yurino, M. Kitabatake, T. Ito, T. Kuriyama, and K. Matsushima Breakdown of Mucosal Immunity in the Gut and Resultant Systemic Sensitization by Oral Antigens in a Murine Model for Systemic Lupus Erythematosus J. Immunol., May 1, 2005; 174(9): 5499 - 5506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Youn, M. Miller, K. J. Baek, J. W. Han, J. Nayar, S. Y. Lee, K. McElwain, S. McElwain, E. Raz, and D. H. Broide Immunostimulatory DNA Reverses Established Allergen-Induced Airway Remodeling J. Immunol., December 15, 2004; 173(12): 7556 - 7564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Sukkar, R. Issa, S. Xie, U. Oltmanns, R. Newton, and K. F. Chung Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-{gamma} and TNF-{alpha} and regulation by TGF-{beta} and corticosteroids Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1230 - L1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jakubzick, H. Wen, A. Matsukawa, M. Keller, S. L. Kunkel, and C. M. Hogaboam Role of CCR4 Ligands, CCL17 and CCL22, During Schistosoma mansoni Egg-Induced Pulmonary Granuloma Formation in Mice Am. J. Pathol., October 1, 2004; 165(4): 1211 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Gounni, Q. Hamid, S. M. Rahman, J. Hoeck, J. Yang, and L. Shan IL-9-Mediated Induction of Eotaxin1/CCL11 in Human Airway Smooth Muscle Cells J. Immunol., August 15, 2004; 173(4): 2771 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Cronshaw, C. Owen, Z. Brown, and S. G. Ward Activation of Phosphoinositide 3-Kinases by the CCR4 Ligand Macrophage-Derived Chemokine Is a Dispensable Signal for T Lymphocyte Chemotaxis J. Immunol., June 15, 2004; 172(12): 7761 - 7770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, N. N. Jarjour, W. W. Busse, and E. A. B. Kelly Enhanced Generation of Helper T Type 1 and 2 Chemokines in Allergen-induced Asthma Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1118 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Katakura, M. Miyazaki, M. Kobayashi, D. N. Herndon, and F. Suzuki CCL17 and IL-10 as Effectors That Enable Alternatively Activated Macrophages to Inhibit the Generation of Classically Activated Macrophages J. Immunol., February 1, 2004; 172(3): 1407 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Dudda, J. C. Simon, and S. Martin Dendritic Cell Immunization Route Determines CD8+ T Cell Trafficking to Inflamed Skin: Role for Tissue Microenvironment and Dendritic Cells in Establishment of T Cell-Homing Subsets J. Immunol., January 15, 2004; 172(2): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Conroy, L. A. Jopling, C. M. Lloyd, M. R. Hodge, D. P. Andrew, T. J. Williams, J. E. Pease, and I. Sabroe CCR4 blockade does not inhibit allergic airways inflammation J. Leukoc. Biol., October 1, 2003; 74(4): 558 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sundrud, S. M. Grill, D. Ni, K. Nagata, S. S. Alkan, A. Subramaniam, and D. Unutmaz Genetic Reprogramming of Primary Human T Cells Reveals Functional Plasticity in Th Cell Differentiation J. Immunol., October 1, 2003; 171(7): 3542 - 3549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Faffe, T. Whitehead, P. E. Moore, S. Baraldo, L. Flynt, K. Bourgeois, R. A. Panettieri, and S. A. Shore IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L907 - L914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Y. Vermaelen, D. Cataldo, K. Tournoy, T. Maes, A. Dhulst, R. Louis, J.-M. Foidart, A. Noel, and R. Pauwels Matrix Metalloproteinase-9-Mediated Dendritic Cell Recruitment into the Airways Is a Critical Step in a Mouse Model of Asthma J. Immunol., July 15, 2003; 171(2): 1016 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Carey, D. R. Germolec, J. A. Bradbury, R. A. Gooch, M. P. Moorman, G. P. Flake, R. Langenbach, and D. C. Zeldin Accentuated T Helper Type 2 Airway Response after Allergen Challenge in Cyclooxygenase-1-/- but Not Cyclooxygenase-2-/- Mice Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1509 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bishop and C. M. Lloyd CC Chemokine Ligand 1 Promotes Recruitment of Eosinophils But Not Th2 Cells During the Development of Allergic Airways Disease J. Immunol., May 1, 2003; 170(9): 4810 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.F. Leung, C.K. Wong, C.W.K. Lam, A.M. Li, W.K. Ip, G.W.K. Wong, and T.F. Fok Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children Eur. Respir. J., April 1, 2003; 21(4): 616 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Alferink, I. Lieberam, W. Reindl, A. Behrens, S. Weiss, N. Huser, K. Gerauer, R. Ross, A. B. Reske-Kunz, P. Ahmad-Nejad, et al. Compartmentalized Production of CCL17 In Vivo: Strong Inducibility in Peripheral Dendritic Cells Contrasts Selective Absence from the Spleen J. Exp. Med., March 3, 2003; 197(5): 585 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Soler, T. L. Humphreys, S. M. Spinola, and J. J. Campbell CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking Blood, March 1, 2003; 101(5): 1677 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Goya, R. Villares, A. Zaballos, J. Gutierrez, L. Kremer, J.-A. Gonzalo, R. Varona, L. Carramolino, A. Serrano, P. Pallares, et al. Absence of CCR8 Does Not Impair the Response to Ovalbumin-Induced Allergic Airway Disease J. Immunol., February 15, 2003; 170(4): 2138 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Chung, F. Kuo, J. Kumer, A. S. Motani, C. E. Lawrence, W. R. Henderson Jr., and C. Venkataraman CCR8 Is Not Essential for the Development of Inflammation in a Mouse Model of Allergic Airway Disease J. Immunol., January 1, 2003; 170(1): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Hoover, C. Boulegue, D. Yang, J. J. Oppenheim, K. Tucker, W. Lu, and J. Lubkowski The Structure of Human Macrophage Inflammatory Protein-3alpha /CCL20. LINKING ANTIMICROBIAL AND CC CHEMOKINE RECEPTOR-6-BINDING ACTIVITIES WITH HUMAN beta -DEFENSINS J. Biol. Chem., September 27, 2002; 277(40): 37647 - 37654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cheng, M. Arima, K. Honda, H. Hirata, F. Eda, N. Yoshida, F. Fukushima, Y. Ishii, and T. Fukuda Anti-Interleukin-9 Antibody Treatment Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Model Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Horikawa, T. Nakayama, I. Hikita, H. Yamada, R. Fujisawa, T. Bito, S. Harada, A. Fukunaga, D. Chantry, P. W. Gray, et al. IFN-{gamma}-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis Int. Immunol., July 1, 2002; 14(7): 767 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Miyazaki, S.-i. Nureki, T. Fukami, T. Shigenaga, M. Ando, K. Ito, H. Ando, K. Sugisaki, T. Kumamoto, and T. Tsuda Elevated Levels of Thymus- and Activation-regulated Chemokine in Bronchoalveolar Lavage Fluid from Patients with Eosinophilic Pneumonia Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1125 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Foxman, M. Zhang, S. D. Hurst, T. Muchamuel, D. Shen, E. F. Wawrousek, C.-C. Chan, and I. Gery Inflammatory Mediators in Uveitis: Differential Induction of Cytokines and Chemokines in Th1- Versus Th2-Mediated Ocular Inflammation J. Immunol., March 1, 2002; 168(5): 2483 - 2492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Jopling, I. Sabroe, D. P. Andrew, T. J. Mitchell, Y. Li, M. R. Hodge, T. J. Williams, and J. E. Pease The Identification, Characterization, and Distribution of Guinea Pig CCR4 and Epitope Mapping of a Blocking Antibody J. Biol. Chem., February 22, 2002; 277(9): 6864 - 6873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D'AMBROSIO, M. MARIANI, P. PANINA-BORDIGNON, and F. SINIGAGLIA Chemokines and Their Receptors Guiding T Lymphocyte Recruitment in Lung Inflammation Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1266 - 1275. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or mMDC
(
) at 10 nM was preincubated with or without the indicated
concentration of 5H5 for 30 min. 5H5 could inhibit TARC-induced
chemotaxis at 1 and 10 µg/ml, but could not inhibit MDC-induced
chemotaxis at 10 µg/ml. Values were expressed as the percentage of
input cells that migrated to the lower wells. The mean ± SE of
three independent experiments is shown.
, macrophages; Neu, neutrophils. Values shown are the
mean ± SE of four to five animals per group. *, Values
significantly different from PBS-treated groups (p
< 0.05). +, Values significantly different from anti-TARC
Ab-treated groups (p < 0.05).
